Scribe Therapeutics Stock Soars 67% Following $129 Million IPO
Scribe Therapeutics made a notable entrance on the Nasdaq, raising $128.7 million in its initial public offering and seeing its stock price increase by about 67% on the first day of trading. The company sold 8.58 million shares at $15 each, which was at the top end of its anticipated price range, under the ticker symbol SCTX. Founded between 2017 and 2018 from UC Berkeley’s Doudna Lab, Scribe Therapeutics is focused on CRISPR technology, specifically utilizing epigenetic silencing to regulate gene expression without permanently altering DNA.
The company's lead candidate, STX-1150, is currently undergoing Phase 1 clinical trials aimed at lowering LDL cholesterol levels. Additionally, Scribe is developing STX-1200, a preclinical program targeting lipoprotein(a) reduction, which has shown promising results in preclinical models with over 90% knockdown of Lp(a).
For Your Trading Desk
Sponsor Spike Success.
Scribe's initial funding included a $20 million investment from Andreessen Horowitz, and by March 2026, the company reported a cash position of approximately $50 million. The firm has also secured partnerships with major pharmaceutical companies such as Biogen, Sanofi, and Eli Lilly, which provide milestone payments and potential royalties, allowing Scribe to generate revenue even before its products reach the market.
Initially, Scribe planned a smaller offering but expanded it to meet investor demand, ultimately landing at the sale of 8.58 million shares at $15 each. Despite the successful IPO, Scribe remains a clinical-stage company, and with STX-1150 still in Phase 1 trials, there are years of testing, regulatory reviews, and potential challenges ahead before any revenue can be realized. Investors purchasing shares at post-IPO prices are paying a premium compared to those who acquired shares at the initial offering price of $15.




